Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?
Wynn
Richard L
RL
Department of Oral Craniofacial Biological Sciences, Dental School, University of Maryland at Baltimore, USA.
D019386:Alendronate / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced / Q000453:epidemiology; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D019379:Teriparatide / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D019379:Teriparatide; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D002118:Calcium; D019386:Alendronate